GRO Biosciences develops a synthetic biology platform that provides access to non-standard amino acids (NSAAs) for therapeutic applications.

GRO Biosciences

IPhone / Mobile Compatible

Viewport Meta

Google Tag Manager

Apple Mobile Web Clips Icon

Google Font API

Google Analytics

WordPress

Global Site Tag

Font Awesome

Mobile Non Scaleable Content

Co-Founder and CEO

Dan Mandell

Associate Director, Application Sciences

Bijou Bose

Biotechnology Project Manager

Karen Bui

Sales and Support

Scott Frankenthaler

Engineering

Anushka Saha

Chief Scientific Officer

Christopher Gregg

Dana Braff

Derek Clay

Chief Business Officer

Edward Stewart

J. Marisha Collins

Kevin Bitterman

Dan Becker

Geoffrey W. Smith

Lucio Iannone

Bruce Beutel

Daniel J. Mandell

Co-Founder and Chief Executive Officer

Ross Thyer

Co-Founder and Scientific Advisor

Chief Science Officer, Co-Founder, Director

Justin Feng

Principal Scientist

Edward J. Stewart

Tracey Lodie

Chief Development Officer

Benjamin Stranges

Marc Lajoie

Co-Founder and Advisor

United States Medical Companies with Early Stage Venture Funding

Companies With Fewer Than 100 Employees (Top 10K)

Companies With Less Than $1M in Revenue (Top 10K)

Therapeutics Companies with Early Stage Venture Funding

GRO Biosciences is leveraging breakthrough technologies from computational protein design and synthetic biology to develop best-in-class protein therapeutics with enhanced properties. The company has established multiple genomically recoded strains of bacteria that can incorporate non-standard amino acids into proteins to confer increased potency, stability, and targeted delivery. 

GRO Biosciences is applying its technology platform to develop improved protein therapeutics for diabetes, growth disorders, and autoimmunity.

Access Biotechnology

Atlas Venture

Series B - GRO Biosciences

Leaps by Bayer

Redmile Group

Series A - GRO Biosciences

National Science Foundation

Grant - GRO Biosciences

Digitalis Ventures

Seed Round - GRO Biosciences

Boston

Massachusetts

United States

North America

GRO Biosciences Closes $60M Series B

GRO Biosciences Closes $60.3M Series B Financing

GRObio Secures $60.3 Million in Series B Financing to Advance Protein Therapeutics

GRO Biosciences closes $60 million Series B financing

GRO Bio gathers $60M series B to take gout rival to Krystexxa into clinic

George Church spinout to enter clinic with new $60M investment

GRO Biosciences: Protein Therapeutics Company Raises $60 Million In Series B

GRO Biosciences Closes $60M Series B Financing Co-Led by Atlas Venture and Access Biotechnology

India

Asia

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general	Nov 24, 2024 12:58 PM	c94d4103
public peers	general	Oct 24, 2024 5:05 PM	41db365d
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Nov 23, 2024 5:24 PM	756d0680
company summary	general
signals	general	Oct 24, 2024 5:05 PM	b810aae5
crunchbase trigger	general	Oct 28, 2024 1:50 PM	c7fdb93c
crunchbase profile	general	Oct 29, 2024 9:01 AM	6655fda0
li profile	general
translate crunchbase fundingrounds	general	Nov 6, 2024 3:12 PM	e1cb7531
peers	general	Oct 24, 2024 5:05 PM	2d4f3b7e
news basic	general	Oct 24, 2024 5:05 PM	1ed09c94
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

GROB

COM:GROBIO

GRO Biosciences